Angie You
Director/Board Member at ORIC PHARMACEUTICALS, INC.
Net worth: - $ as of 31/03/2024
Profile
Angie J.
You is currently an Independent Director at Oric Pharmaceuticals, Inc., a Senior Advisor at Frazier Management LLC, and an Advisor at Casdin Capital.
Previously, she served as the Chief Executive Officer & Director at Amunix Pharmaceuticals, Inc., Chief Business & Strategy Officer at Sierra Oncology, Inc., and Chief Business Officer at Synosia Therapeutics AG, among other positions.
She also worked as a Management Consultant at McKinsey & Co., Inc. Dr. You holds graduate and doctorate degrees from Harvard University and an undergraduate degree from Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ORIC PHARMACEUTICALS INC
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Angie You active positions
| Companies | Position | Start |
|---|---|---|
| ORIC PHARMACEUTICALS, INC. | Director/Board Member | 09/11/2021 |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | 01/01/2022 |
Casdin Capital /Private Equity/
 Casdin Capital /Private Equity/ Investment ManagersFinance Casdin Capital /Private Equity/ (Casdin Capital) is a private equity/venture capital subsidiary of Casdin Capital LLC founded in 2012 by Eli Casdin. The firm is headquartered in New York. | Consultant / Advisor | - |
Former positions of Angie You
| Companies | Position | End |
|---|---|---|
| RAYZEBIO, INC. | Director/Board Member | 26/02/2024 |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Chief Executive Officer | 01/01/2022 |
| SIERRA ONCOLOGY, INC. | Corporate Officer/Principal | 01/12/2018 |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/01/2013 |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Corporate Officer/Principal | 01/08/2007 |
Training of Angie You
| Harvard University | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| RAYZEBIO, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Venrock Associates
Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Finance |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Finance |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Health Technology |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA. | Health Technology |
Casdin Capital /Private Equity/
Casdin Capital /Private Equity/ Investment ManagersFinance Casdin Capital /Private Equity/ (Casdin Capital) is a private equity/venture capital subsidiary of Casdin Capital LLC founded in 2012 by Eli Casdin. The firm is headquartered in New York. | Finance |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
- Stock Market
- Insiders
- Angie You
